Cardiovascular effects of migraine therapy.
Baker
William L
WL
Department of Pharmacy Practice, UCONN School of Pharmacy, Hartford, CT 0615, USA.
Folstad
Jon
J
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control; D002319:Cardiovascular System / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D018579:Patient Selection; D015995:Prevalence; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use; D017678:Sex Distribution; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000806:Angiotensin-Converting Enzyme Inhibitors; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D002121:Calcium Channel Blockers; D017366:Serotonin Receptor Agonists